Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | CRY1 | Q16526 | 11/20 | 0.37 |
| ▸ | CRY2 | Q49AN0 | 11/20 | 0.37 |
| ▸ | PER2 | O15055 | 10/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | PARG | Q86W56 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922170 | 0.86 | CYP2C9 (0.54) | CYP2C9NR1I2CRY1CRY2PER2 | |
| SCHEMBL3917989 | 0.85 | CYP2C9 (0.42) | CYP2C9NR1I2PTGDR2PARGHDAC1 | |
| SCHEMBL3929676 | 0.85 | CYP2C9 (0.39) | CYP2C9NR1I2CRY1CRY2PER2 | |
| SCHEMBL3929284 | 0.83 | CYP2C9 (0.41) | CYP2C9NR1I2PTGDR2HDAC1HDAC8 | |
| SCHEMBL3922130 | 0.83 | PIK3R1 (0.44) | CYP2C9NR1I2HDAC1HDAC8HDAC6 | |
| SCHEMBL3922914 | 0.83 | CYP2C9 (0.39) | CYP2C9NR1I2CRY1CRY2PER2 | |
| SCHEMBL4068112 | 0.83 | CYP2C9 (0.39) | CYP2C9NR1I2PTGDR2PARGHDAC1 | |
| SCHEMBL3920019 | 0.82 | CYP2C9 (0.50) | CYP2C9NR1I2PER2PTGDR2HDAC1 | |
| SCHEMBL3920862 | 0.82 | CYP2C9 (0.39) | CYP2C9NR1I2PTGDR2PARGHDAC1 | |
| SCHEMBL4069350 | 0.81 | CYP2C9 (0.38) | CYP2C9NR1I2PTGDR2PARGHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786807-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2009-07-29 | — | — | EP | claimed |
| US-7479489-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-01-20 | — | — | US | claimed |
| EP-1786807-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-05-23 | — | — | EP | claimed |
| WO-2006021340-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-03-02 | — | — | WO | claimed |
| US-20060040927-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-02-23 | — | — | US | claimed |
| EP-1786807-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-7479489-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-01-20 | — | — | US | disclosed |
| EP-1786807-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006021340-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-03-02 | — | — | WO | disclosed |
| US-20060040927-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040927-A1 | Heterocyclic antiviral compounds | HAVCR2, POLR1A, HCCS | CYP2C9 366/4885NR1I2 239/4885CRY1 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.